EGFR and Alzheimer disease: In patients with EGFR variation–positive AD, the median PFS of first-line EGFR-TKI was 16.6 months (95% CI, 16.0 to 17.7 months) and 17.4 months (95% CI, 16.7 to 18.4 months) in period I and II, respectively.